Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for the Week Ending March 7, 2020

3/10/2020

 
Regulatory Update
 
The FDA approved isatuximab (Sarclisa, Sanofi) on 3/2/2020 to be given in combination with pomalidomide (Revlimid, Celgene) and dexamethasone for the treatment of multiple myeloma in patients that received two or more prior therapies including lenalidomide and a proteasome inhibitor. Sanofi set WAC for a 5 ml vial of isatuximab at $650 and $3,250 for a 25 ml vial.
 
The FDA approved osilodrostat (Isturisa, Novartis) on 3/6/2020 for the treatment of adults with Cushing's disease who either are candidates for pituitary gland surgery or in whom the disease persists after surgery.
 
Redhill launched amoxicillin, omeprazole, rifabutin (Talicia) on 3/9/2020 at a WAC of $650 for 168 capsules. Omeprazole, amoxicillin and rifabutin was approved on 11/5/2019 for the treatment of Helicobacter pylori infection in adults.
 
The FDA accepted the NDA for Urovant/Kyorin/Merck’s vibegron for the treatment of overactive bladder and set a PDUFA date of December 26, 2020.
 
The FDA accepted the resubmitted NDA for Trevena’s oliceridine as a treatment for moderate-to-severe acute pain and set a PDUFA date of 8/7/2020.
 
The FDA accepted the BLA for Pfizer’s tanezumab, in March 2020, for the treatment of chronic osteoarthritis pain in patients who have experienced inadequate pain relief with other analgesics and set a PDUFA date in December 2020.
 
The FDA granted a Rare Pediatric Disease designation to Stealth BioTherapeutics’ elamipretide for the treatment of Barth syndrome.
 
Mallinckrodt initiated a rolling submission NDA for terlipressin for the treatment of patients with hepatorenal syndrome type 1 in March 2020.
 
Janssen submitted an MAA for ponesimod for treatment of adults with relapsing-remitting multiple sclerosis.
 
Announced Research Updates
 
AstraZeneca announced that in the 1,126 patient, Phase III, open-label, DANUBE trial, neither durvalumab plus tremelimumab nor durvalumab monotherapy improved overall survival compared to standard-of-care chemotherapy in patients with unresectable stage IV bladder cancer. 
 
Published Research Updates
 
In a 279 patient trial, there was no difference in mortality in patients treated with levosimendan compared to intra-aortic balloon counterpulsation in patients with poor left ventricular function undergoing coronary artery bypass grafting (CABG) with ejection fraction less than 35%.
 
In a 65 patient, 4-day, Phase II, open-label trial, treatment with terlipressin reduced portal venous pressure by 1.5 mmHg in patients with portal vein pressure >12 mmHg after hepatectomy.
 
In the 48-week, 616 patient, Phase III ATLAS Trial, 1.6% of patients that received a monthly IM injection of cabotegravir and rilpivirine had an HIV-1 RNA of 50 copies/mL or > compared to 1% of patients that continued a standard daily thee drug oral regimen in patients with plasma HIV-1 RNA levels of less than 50 copies per milliliter for at least 6 months while taking standard oral antiretroviral therapy. In the 48-week, 566 patient, Phase III FLAIR trial, patients were treated with 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine, then randomized to monthly IM injection of cabotegravir and rilpivirine or continuation of dolutegravir-abacavir-lamivudin. After 48 weeks 2.1% of patients that received cabotegravir/rilpivirine monthly had an HIV-1 RNA of 50 copies/mL or > compared to 2.5% of patients that continued dolutegravir-abacavir-lamivudin in patients with with HIV-1 infection who had not previously received antiretroviral therapy.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.